Schonfeld Strategic Advisors LLC Cullinan Oncology, Inc. Transaction History

Schonfeld Strategic Advisors LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$10.17 - $19.02 $823,017 - $1.54 Million	-80,926 Reduced 57.39%	60,074 $1.02 Million
Q4 2023 Feb 14, 2024	BUY	$7.89 - $10.23 $151,488 - $196,416	19,200 Added 15.76%	141,000 $1.44 Million
Q3 2023 Nov 14, 2023	BUY	$9.05 - $11.72 $151,135 - $195,724	16,700 Added 15.89%	121,800 $1.1 Million
Q2 2023 Aug 14, 2023	BUY	$8.8 - $13.4 $622,160 - $947,380	70,700 Added 205.52%	105,100 $1.13 Million
Q1 2023 May 15, 2023	BUY	$10.2 - $11.91 $4,079 - $4,764	400 Added 1.18%	34,400 $351,000
Q4 2022 Feb 14, 2023	BUY	$9.72 - $13.62 $330,480 - $463,080	34,000 New	34,000 $358,000
Q4 2021 Feb 14, 2022	SELL	$15.36 - $25.0 $550,778 - $896,450	-35,858 Closed	0 $0
Q3 2021 Nov 16, 2021	BUY	$22.56 - $29.68 $808,956 - $1.06 Million	35,858 New	35,858 $809,000
Q2 2021 Aug 16, 2021	SELL	$24.96 - $41.25 $1.21 Million - $2 Million	-48,373 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$28.0 - $53.42 $1.35 Million - $2.58 Million	48,373 New	48,373 $2.02 Million

140

65.9M

77.2K

15.9K

Ticker CGEM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,612,200
Market Cap $764M
Description
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.